Drug Plan Trends Report: A snapshot of what’s coming down the pike
Medavie Blue Cross has also seen a significant decline in new patient starts for hepatitis C medications, says Chris Goguen, the insurer’s strategic pharmaceutical partnerships lead in Moncton, N.B. Demand is now one-fifth of the volume it was a year-and-a-half ago, although there may be a slight bump if and when the medications are approved for more indications, says Christine Than, a pharmacist and drug solutions specialist at Aon Hewitt in Montreal.
About the Author
Chris Goguen
Chris joined Medavie Blue Cross in 2015, with 25 years of experience as a senior leader within the research-based pharmaceutical industry in Canada. With the majority of his career focussed on External Affairs, including strategy and relationship development with governments, private payers & other health stakeholders across Canada, Chris has developed expertise in drug pricing, access, negotiation and patient health management strategies. He has played a lead role in development and implementation of numerous disease [drug] management partnership programs, impacting both public and private health system outcomes.
CAF, RCMP, VAC